SpyGlass Pharma, Inc. SGP
—
27.07
(0.58)
(2.10%)
as of 25 Sep
- Market cap
- $924.8M
- P/E
- 0.0×
Follow SGP
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+4 more TTM periods Free account |
— | — | — | (51.34%) | |
| 0.00% | 0.00% | 0.00% | (42.05%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | (22.08%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | — | 0.00 | (1.39) | |
Free Cash Flow |
(30.42) | — | (37.96) | (46.36) | |
Capital Expenditures |
(0.81) | — | (1.04) | (2.81) | |
Piotroski F-Score |
— | — | — | 1.00 | |
| Other line items | |||||
Cash ROIC |
(96.11%) | 0.00% | (7.37%) | (9.33%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | — | 0.00 | 0.85 | |
Depreciation/Fixed assets |
0.24 | 0.00 | 0.26 | 0.19 | |
Capex/Depreciation |
(1.61) | — | (1.46) | (3.02) | |
Revenue per Share |
— | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | — | 0.00 | (1.30) | |
Capex per Share |
0.00 | — | 0.00 | (0.08) | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
— | — | — | 0.00% |
Columns are period end dates